Moberg Pharma
12,41 SEK +3,33%6 investorer følger denne virksomhed
Moberg Pharma is a Swedish pharmaceutical company focused on the commercialization of proprietary medicines based on proven substances. The company mainly works in nail fungus, where Moberg Pharma is developing a new external treatment. The company has agreements with commercial partners on site in Europe and Asia, among other places. The head office is in Bromma.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
MOB
Daglig lav / høj pris
12 / 12,63
SEK
Markedsværdi
594,19 mio. SEK
Aktieomsætning
5,23 mio. SEK
Volumen
426 t
Seneste videoer
Finanskalender
Delårsrapport
12.11.2024
Årsrapport
11.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
IBKR Financial Services AG, W8IMY | 9,9 % | 9,9 % |
Östersjöstiftelsen | 9,0 % | 9,0 % |
Avanza Pension | 4,6 % | 4,6 % |
Kjelsmark Holding ApS | 3,3 % | 3,3 % |
Moberg Pharma AB | 2,5 % | 2,5 % |
CBNY-National Financial Services Ll | 2,4 % | 2,4 % |
Morgan Stanley & Co Intl Plc, W-8imy Qdd | 2,1 % | 2,1 % |
UBS AG London Branch, W8imy | 2,0 % | 2,0 % |
Nordnet Pensionsförsäkring | 1,9 % | 1,9 % |
SEB AB, Luxembourg Branch, W8imy | 1,9 % | 1,9 % |
ViserAlle indholdstyper
Redeye: Moberg Pharma - The Swedish market leader
Moberg Pharma's interim report January - June 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools